WCG Clinical Inc

1. Eli Lilly and Company $1,323,384 14 payments
2. Novavax Inc $863,029 45 payments
3. Janssen Research & Development, LLC $795,513 106 payments
4. Teva Pharmaceuticals USA, Inc. $432,195 88 payments
5. Sumitomo Pharma America, Inc. $374,496 100 payments
6. GlaxoSmithKline, LLC. $337,496 60 payments
7. ACADIA Pharmaceuticals Inc $200,175 49 payments
8. AbbVie, Inc. $188,681 41 payments
9. Provepharm Inc. $60,128 35 payments
10. Galderma Laboratories, L.P. $49,893 16 payments

1. A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone Or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight Or Obese Men and Women $806,953 3 payments
2. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $632,048 80 payments
3. Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to younger than 12 Years $485,100 22 payments
4. A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $429,560 65 payments
5. A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone Or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight Or Obese Men and Women $388,413 2 payments
6. A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $254,037 63 payments
7. A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in Children 6 Months to < 12 Years of Age $251,472 9 payments
8. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms $163,465 26 payments
9. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $162,065 32 payments
10. Acp-204-006 $142,190 39 payments

1. Other $16,541 30 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.